SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Condition: Triple-negative Breast Cancer Intervention: Drug: SHR-1210+Albumin-bound paclitaxel + epirubicin Sponsor: Henan Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Abraxane | Breast Cancer | Cancer | Cancer & Oncology | Hospitals | Neoadjuvant Therapy | Research